Protein kinase A alterations in endocrine tumors

Hormone and Metabolic Research

Volumn 44, Issue 10, 2012, Pages 741-748

  Yu, B ^a,b   Ragazzon, B ^a,b   Rizk Rabin, M ^a,b   Bertherat, J ^a,b,c  

^a INSTITUT COCHIN   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Université Paris Descartes ^*  (France)

Author keywords

adrenal tumors; cAMP; pituitary tumors; PKA

Indexed keywords

8 CHLOROADENOSINE 3',5' PHOSPHATE; BETA CATENIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE REGULATORY SUBUNIT IALPHA; CYCLIC AMP DEPENDENT PROTEIN KINASE REGULATORY SUBUNIT IIALPHA; CYCLIN B; CYCLIN D1; MESSENGER RNA; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA;

ADRENAL CORTEX TUMOR; APOPTOSIS; BREAST CARCINOMA; CARCINOGENESIS; CARNEY COMPLEX; CELL PROLIFERATION; CHROMOSOME 17Q; COLON CARCINOMA; CUSHING SYNDROME; ENDOCRINE TUMOR; EPITHELIAL MESENCHYMAL TRANSITION; EXON; GENE EXPRESSION; GENE MUTATION; GROWTH HORMONE SECRETING ADENOMA; HAPLOINSUFFICIENCY; HUMAN; HYPERPIGMENTATION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIMARY PIGMENTED NODULAR ADRENOCORTICAL DYSPLASIA; PRIORITY JOURNAL; REVIEW; SERIAL ANALYSIS OF GENE EXPRESSION; TESTIS TUMOR; THYROID CANCER; THYROID TUMOR;

ADRENAL CORTEX; ANIMALS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENDOCRINE GLAND NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN SUBUNITS;

EID: 84866088983     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0032-1316292     Document Type: Review

References (75)

1. Gloerich M, Bos J L. Epac: defining a new mechanism for cAMP action. Annu Rev Pharmacol Toxicol: 2010; 50 355 375
2. Corbin J D, Keely S L, Park C R. The distribution and dissociation of cyclic adenosine 3:5-monophosphate-dependent protein kinases in adipose, cardiac, and other tissues. J Biol Chem: 1975; 250 218 225
3. Pearce L R, Komander D, Alessi D R. The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol: 2010; 11 9 22
4. Shabb J B. Physiological substrates of cAMP-dependent protein kinase. Chem Rev: 2001; 101 2381 2411
5. Landis C A, Masters S B, Spada A, Pace A M, Bourne H R, Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature: 1989; 340 692 696
6. Weinstein L S, Shenker A, Gejman P V, Merino M J, Friedman E, Spiegel A M. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med: 1991; 325 1688 1695
7. Porcellini A, Ciullo I, Pannain S, Fenzi G, Avvedimento E. Somatic mutations in the VI transmembrane segment of the thyrotropin receptor constitutively activate cAMP signalling in thyroid hyperfunctioning adenomas. Oncogene: 1995; 11 1089 1093
8. Horvath A, Mericq V, Stratakis C A. Mutation in PDE8B, a cyclic AMP-specific phosphodiesterase in adrenal hyperplasia. N Engl J Med: 2008; 358 750 752
9. Libe R, Horvath A, Vezzosi D, Fratticci A, Coste J, Perlemoine K, Ragazzon B, Guillaud-Bataille M, Groussin L, Clauser E, Raffin-Sanson M L, Siegel J, Moran J, Drori-Herishanu L, Faucz F R, Lodish M, Nesterova M, Bertagna X, Bertherat J, Stratakis C A. Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype. J Clin Endocrinol Metab: 2011; 96 E208 E214
10. Riou J P, Evain D, Perrin F, Saez J M. Adenosine 35-cyclic monophosphate dependent protein kinase in human adrenocortical tumors. J Clin Endocrinol Metab: 1977; 44 413 419
11. Carney J A, Gordon H, Carpenter P C, Shenoy B V, Go V L. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore): 1985; 64 270 283
12. Stratakis C A. Genetics of adrenocortical tumors: Carney complex. Ann Endocrinol (Paris). 2001; 62 180 184
13. Vezzosi D, Bertherat J, Groussin L. Pathogenesis of benign adrenocortical tumors. Best Pract Res Clin Endocrinol Metab: 2010; 24 893 905
14. Rothenbuhler A, Stratakis C A. Clinical and molecular genetics of Carney complex. Best Pract Res Clin Endocrinol Metab: 2010; 24 389 399
15. Groussin L, Horvath A, Jullian E, Boikos S, Rene-Corail F, Lefebvre H, Cephise-Velayoudom F L, Vantyghem M C, Chanson P, Conte-Devolx B, Lucas M, Gentil A, Malchoff C D, Tissier F, Carney J A, Bertagna X, Stratakis C A, Bertherat J. A PRKAR1A mutation associated with primary pigmented nodular adrenocortical disease in 12 kindreds. J Clin Endocrinol Metab: 2006; 91 1943 1949
16. Groussin L, Jullian E, Perlemoine K, Louvel A, Leheup B, Luton J P, Bertagna X, Bertherat J. Mutations of the PRKAR1A gene in Cushing's syndrome due to sporadic primary pigmented nodular adrenocortical disease. J Clin Endocrinol Metab: 2002; 87 4324 4329
17. Kirschner L S, Carney J A, Pack S D, Taymans S E, Giatzakis C, Cho Y S, Cho-Chung Y S, Stratakis C A. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet: 2000; 26 89 92
18. Casey M, Vaughan C J, He J, Hatcher C J, Winter J M, Weremowicz S, Montgomery K, Kucherlapati R, Morton C C, Basson C T. Mutations in the protein kinase A R1alpha regulatory subunit cause familial cardiac myxomas and Carney complex. J Clin Invest: 2000; 106 R31 R38
19. Bertherat J, Horvath A, Groussin L, Grabar S, Boikos S, Cazabat L, Libe R, Rene-Corail F, Stergiopoulos S, Bourdeau I, Bei T, Clauser E, Calender A, Kirschner L S, Bertagna X, Carney J A, Stratakis C A. Mutations in regulatory subunit type 1 A of cyclic adenosine 5-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J Clin Endocrinol Metab: 2009; 94 2085 2091
20. Zawadzki K M, Taylor S S. cAMP-dependent protein kinase regulatory subunit type IIbeta: active site mutations define an isoform-specific network for allosteric signaling by cAMP. J Biol Chem: 2004; 279 7029 7036
21. Kirschner L S, Sandrini F, Monbo J, Lin J P, Carney J A, Stratakis C A. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the carney complex. Hum Mol Genet: 2000; 9 3037 3046
22. Horvath A, Bertherat J, Groussin L, Guillaud-Bataille M, Tsang K, Cazabat L, Libe R, Remmers E, Rene-Corail F, Faucz F R, Clauser E, Calender A, Bertagna X, Carney J A, Stratakis C A. Mutations and polymorphisms in the gene encoding regulatory subunit type 1-alpha of protein kinase A (PRKAR1A): an update. Hum Mutat: 2010; 31 369 379
23. Sandrini F, Stratakis C. Clinical and molecular genetics of Carney complex. Mol Genet Metab: 2003; 78 83 92
24. Greene E L, Horvath A D, Nesterova M, Giatzakis C, Bossis I, Stratakis C A. In vitro functional studies of naturally occurring pathogenic PRKAR1A mutations that are not subject to nonsense mRNA decay. Hum Mutat: 2008; 29 633 639
25. Meoli E, Bossis I, Cazabat L, Mavrakis M, Horvath A, Stergiopoulos S, Shiferaw M L, Fumey G, Perlemoine K, Muchow M, Robinson-White A, Weinberg F, Nesterova M, Patronas Y, Groussin L, Bertherat J, Stratakis C A. Protein kinase A effects of an expressed PRKAR1A mutation associated with aggressive tumors. Cancer Res: 2008; 68 3133 3141
26. Groussin L, Kirschner L S, Vincent-Dejean C, Perlemoine K, Jullian E, Delemer B, Zacharieva S, Pignatelli D, Carney J A, Luton J P, Bertagna X, Stratakis C A, Bertherat J. Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD. Am J Hum Genet: 2002; 71 1433 1442
27. Blyth M, Huang S, Maloney V, Crolla J A, Karen Temple I A. 2.3Mb deletion of 17q24.2-q24.3 associated with Carney Complex plus'. Eur J Med Genet: 2008; 51 672 678
28. Horvath A, Bossis I, Giatzakis C, Levine E, Weinberg F, Meoli E, Robinson-White A, Siegel J, Soni P, Groussin L, Matyakhina L, Verma S, Remmers E, Nesterova M, Carney J A, Bertherat J, Stratakis C A. Large deletions of the PRKAR1A gene in Carney complex. Clin Cancer Res: 2008; 14 388 395
29. Patronas Y, Horvath A, Greene E, Tsang K, Bimpaki E, Haran M, Nesterova M, Stratakis C A. In Vitro Studies of Novel PRKAR1A Mutants that Extend the Predicted RIalpha Protein Sequence into the 3'-Untranslated Open Reading Frame: Proteasomal Degradation Leads to RIalpha Haploinsufficiency and Carney Complex. J Clin Endocrinol Metab: 2012; 97 E496 E502
30. Vezzosi D, Vignaux O, Dupin N, Bertherat J. Carney complex: Clinical and genetic 2010 update. Ann Endocrinol (Paris). 2010; 71 486 493
31. Pereira A M, Hes F J, Horvath A, Woortman S, Greene E, Bimpaki E, Alatsatianos A, Boikos S, Smit J W, Romijn J A, Nesterova M, Stratakis C A. Association of the M1V PRKAR1A mutation with primary pigmented nodular adrenocortical disease in two large families. J Clin Endocrinol Metab: 2010; 95 338 342
32. Bertherat J, Groussin L, Sandrini F, Matyakhina L, Bei T, Stergiopoulos S, Papageorgiou T, Bourdeau I, Kirschner L S, Vincent-Dejean C, Perlemoine K, Gicquel C, Bertagna X, Stratakis C A. Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. Cancer Res: 2003; 63 5308 5319
33. Kirschner LS. PRKAR1A and the evolution of pituitary tumors. Mol Cell Endocrinol: 2010; 326 3 7
34. Takano K, Yasufuku-Takano J, Morita K, Mori S, Takei M, Osamura R Y, Teramoto A, Fujita T. Evidence that PKA activity is constitutively activated in human GH-secreting adenoma cells in a patient with Carney complex harbouring a PRKAR1A mutation. Clin Endocrinol (Oxf): 2009; 70 769 775
35. Lania A G, Mantovani G, Ferrero S, Pellegrini C, Bondioni S, Peverelli E, Braidotti P, Locatelli M, Zavanone M L, Ferrante E, Bosari S, Beck-Peccoz P, Spada A. Proliferation of transformed somatotroph cells related to low or absent expression of protein kinase a regulatory subunit 1A protein. Cancer Res: 2004; 64 9193 9198
36. Mantovani G, Bondioni S, Ferrero S, Gamba B, Ferrante E, Peverelli E, Corbetta S, Locatelli M, Rampini P, Beck-Peccoz P, Spada A, Lania A G. Effect of cyclic adenosine 3,5-monophosphate/protein kinase a pathway on markers of cell proliferation in nonfunctioning pituitary adenomas. J Clin Endocrinol Metab: 2005; 90 6721 6724
37. Sandrini F, Matyakhina L, Sarlis N J, Kirschner L S, Farmakidis C, Gimm O, Stratakis C A. Regulatory subunit type I-alpha of protein kinase A (PRKAR1A): a tumor-suppressor gene for sporadic thyroid cancer. Genes Chromosomes Cancer: 2002; 35 182 192
38. Gaujoux S, Tissier F, Ragazzon B, Rebours V, Saloustros E, Perlemoine K, Vincent-Dejean C, Meurette G, Cassagnau E, Dousset B, Bertagna X, Horvath A, Terris B, Carney J A, Stratakis C A, Bertherat J. Pancreatic ductal and acinar cell neoplasms in Carney complex: a possible new association. J Clin Endocrinol Metab: 2011; 96 E1888 E1895
39. Rohlff C, Clair T, Cho-Chung Y S. 8-Cl-cAMP induces truncation and down-regulation of the RI alpha subunit and up-regulation of the RII beta subunit of cAMP-dependent protein kinase leading to type II holoenzyme-dependent growth inhibition and differentiation of HL-60 leukemia cells. J Biol Chem: 1993; 268 5774 5782
40. Bossis I, Stratakis C A. Minireview: PRKAR1A: normal and abnormal functions. Endocrinology: 2004; 145 5452 5458
41. Neary C L, Nesterova M, Cho Y S, Cheadle C, Becker K G, Cho-Chung Y S. Protein kinase A isozyme switching: eliciting differential cAMP signaling and tumor reversion. Oncogene: 2004; 23 8847 8856
42. Griffin K J, Kirschner L S, Matyakhina L, Stergiopoulos S G, Robinson-White A, Lenherr S M, Weinberg F D, Claflin E S, Batista D, Bourdeau I, Voutetakis A, Sandrini F, Meoli E M, Bauer A J, Cho-Chung Y S, Bornstein S R, Carney J A, Stratakis C A. A transgenic mouse bearing an antisense construct of regulatory subunit type 1A of protein kinase A develops endocrine and other tumours: comparison with Carney complex and other PRKAR1A induced lesions. J Med Genet: 2004; 41 923 931
43. Vincent-Dejean C, Cazabat L, Groussin L, Perlemoine K, Fumey G, Tissier F, Bertagna X, Bertherat J. Identification of a clinically homogenous subgroup of benign cortisol-secreting adrenocortical tumors characterized by alterations of the protein kinase A (PKA) subunits and high PKA activity. Eur J Endocrinol: 2008; 158 829 839
44. Mantovani G, Lania A G, Bondioni S, Peverelli E, Pedroni C, Ferrero S, Pellegrini C, Vicentini L, Arnaldi G, Bosari S, Beck-Peccoz P, Spada A. Different expression of protein kinase A (PKA) regulatory subunits in cortisol-secreting adrenocortical tumors: relationship with cell proliferation. Exp Cell Res: 2008; 314 123 130
45. Lignitto L, Sepe M, Carlucci A, Feliciello A. An intimate connection between ubiquitination and compartmentalized cAMP signaling. Cell Cycle: 2011; 10 2051 2052
46. Yin Z, Pringle D R, Jones G N, Kelly K M, Kirschner L S. Differential Role of PKA Catalytic Subunits in Mediating Phenotypes Caused by Knockout of the Carney Complex Gene Prkar1a. Mol Endocrinol: 2011; 25 1786 1793
47. Amieux P S, Howe D G, Knickerbocker H, Lee D C, Su T, Laszlo G S, Idzerda R L, McKnight G S. Increased basal cAMP-dependent protein kinase activity inhibits the formation of mesoderm-derived structures in the developing mouse embryo. J Biol Chem: 2002; 277 27294 27304
48. Griffin K J, Kirschner L S, Matyakhina L, Stergiopoulos S, Robinson-White A, Lenherr S, Weinberg F D, Claflin E, Meoli E, Cho-Chung Y S, Stratakis C A. Down-regulation of regulatory subunit type 1A of protein kinase A leads to endocrine and other tumors. Cancer Res: 2004; 64 8811 8815
49. Kirschner L S, Kusewitt D F, Matyakhina L, Towns W H 2nd, Carney J A, Westphal H, Stratakis C A. A mouse model for the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues. Cancer Res: 2005; 65 4506 4514
50. Yin Z, Williams-Simons L, Parlow A F, Asa S, Kirschner L S. Pituitary-specific knockout of the Carney complex gene Prkar1a leads to pituitary tumorigenesis. Mol Endocrinol: 2008; 22 380 387
51. Yin Z, Jones G N, Towns W H 2nd, Zhang X, Abel E D, Binkley P F, Jarjoura D, Kirschner L S. Heart-specific ablation of Prkar1a causes failure of heart development and myxomagenesis. Circulation: 2008; 117 1414 1422
52. Nadella K S, Kirschner L S. Disruption of protein kinase a regulation causes immortalization and dysregulation of D-type cyclins. Cancer Res: 2005; 65 10307 10315
53. Lambert-Langlais S, Val P, Guyot S, Ragazzon B, Sahut-Barnola I, De Haze A, Lefrancois-Martinez A M, Martinez A. A transgenic mouse line with specific Cre recombinase expression in the adrenal cortex. Mol Cell Endocrinol: 2009; 300 197 204
54. Horvath A, Mathyakina L, Vong Q, Baxendale V, Pang A L, Chan W Y, Stratakis C A. Serial analysis of gene expression in adrenocortical hyperplasia caused by a germline PRKAR1A mutation. J Clin Endocrinol Metab: 2006; 91 584 596
55. Gupte R S, Pozarowski P, Grabarek J, Traganos F, Darzynkiewicz Z, Lee M Y. RIalpha influences cellular proliferation in cancer cells by transporting RFC40 into the nucleus. Cancer Biol Ther: 2005; 4 429 437
56. Moujalled D, Weston R, Anderton H, Ninnis R, Goel P, Coley A, Huang D C, Wu L, Strasser A, Puthalakath H. Cyclic-AMP-dependent protein kinase A regulates apoptosis by stabilizing the BH3-only protein Bim. EMBO Rep: 2011; 12 77 83
57. Tortora G, Pepe S, Cirafici A M, Ciardiello F, Porcellini A, Clair T, Colletta G, Cho-Chung Y S, Bianco A R. Thyroid-stimulating hormone-regulated growth and cell cycle distribution of thyroid cells involve type I isozyme of cyclic AMP-dependent protein kinase. Cell Growth Differ: 1993; 4 359 365
58. Yokozaki H, Budillon A, Tortora G, Meissner S, Beaucage S L, Miki K, Cho-Chung Y S. An antisense oligodeoxynucleotide that depletes RI alpha subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells. Cancer Res: 1993; 53 868 872
59. Robinson-White A, Hundley T R, Shiferaw M, Bertherat J, Sandrini F, Stratakis C A. Protein kinase-A activity in PRKAR1A-mutant cells, and regulation of mitogen-activated protein kinases ERK1/2. Hum Mol Genet: 2003; 12 1475 1484
60. Robinson-White A, Meoli E, Stergiopoulos S, Horvath A, Boikos S, Bossis I, Stratakis C A. PRKAR1A Mutations and protein kinase A interactions with other signaling pathways in the adrenal cortex. J Clin Endocrinol Metab: 2006; 91 2380 2388
61. Ragazzon B, Cazabat L, Rizk-Rabin M, Assie G, Groussin L, Fierrard H, Perlemoine K, Martinez A, Bertherat J. Inactivation of the Carney complex gene 1 (protein kinase A regulatory subunit 1A) inhibits SMAD3 expression and TGF beta-stimulated apoptosis in adrenocortical cells. Cancer Res: 2009; 69 7278 7284
62. Bouizar Z, Ragazzon B, Viou L, Hortane M, Bertherat J, Rizk-Rabin M. 8Cl-cAMP modifies the balance between PKAR1 and PKAR2 and modulates the cell cycle, growth and apoptosis in human adrenocortical H295R cells. J Mol Endocrinol: 2010; 44 331 347
63. Schreyer S A, Cummings D E, McKnight G S, LeBoeuf R C. Mutation of the RIIbeta subunit of protein kinase A prevents diet-induced insulin resistance and dyslipidemia in mice. Diabetes: 2001; 50 2555 2562
64. Enns L C, Morton J F, Treuting P R, Emond M J, Wolf N S, Dai D F, McKnight G S, Rabinovitch P S, Ladiges W C. Disruption of protein kinase A in mice enhances healthy aging. PLoS One: 2009; 4 e5963
65. Nadella K S, Saji M, Jacob N K, Pavel E, Ringel M D, Kirschner L S. Regulation of actin function by protein kinase A-mediated phosphorylation of Limk1. EMBO Rep: 2009; 10 599 605
66. Brunk U T, Terman A. Lipofuscin: mechanisms of age-related accumulation and influence on cell function. Free Radic Biol Med: 2002; 33 611 619
67. Mavrakis M, Lippincott-Schwartz J, Stratakis C A, Bossis I. Depletion of type IA regulatory subunit (RIalpha) of protein kinase A (PKA) in mammalian cells and tissues activates mTOR and causes autophagic deficiency. Hum Mol Genet: 2006; 15 2962 2971
68. Nadella K S, Jones G N, Trimboli A, Stratakis C A, Leone G, Kirschner L S. Targeted deletion of Prkar1a reveals a role for protein kinase A in mesenchymal-to-epithelial transition. Cancer Res: 2008; 68 2671 2677
69. Tadjine M, Lampron A, Ouadi L, Horvath A, Stratakis C A, Bourdeau I. Detection of somatic beta-catenin mutations in primary pigmented nodular adrenocortical disease (PPNAD). Clin Endocrinol (Oxf): 2008; 69 367 373
70. Roy L, McDonald C A, Jiang C, Maroni D, Zeleznik A J, Wyatt T A, Hou X, Davis J S. Convergence of 3,5-cyclic adenosine 5-monophosphate/protein kinase A and glycogen synthase kinase-3beta/beta-catenin signaling in corpus luteum progesterone synthesis. Endocrinology: 2009; 150 5036 5045
71. Bourdeau I, Antonini S R, Lacroix A, Kirschner L S, Matyakhina L, Lorang D, Libutti S K, Stratakis C A. Gene array analysis of macronodular adrenal hyperplasia confirms clinical heterogeneity and identifies several candidate genes as molecular mediators. Oncogene: 2004; 23 1575 1585
72. Gaujoux S, Tissier F, Groussin L, Libe R, Ragazzon B, Launay P, Audebourg A, Dousset B, Bertagna X, Bertherat J. Wnt/beta-catenin and 3,5-cyclic adenosine 5-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. J Clin Endocrinol Metab: 2008; 93 4135 4140
73. Iliopoulos D, Bimpaki E I, Nesterova M, Stratakis C A. MicroRNA signature of primary pigmented nodular adrenocortical disease: clinical correlations and regulation of Wnt signaling. Cancer Res: 2009; 69 3278 3282
74. Robinson-White A J, Hsiao H P, Leitner W W, Greene E, Bauer A, Krett N L, Nesterova M, Stratakis C A. Protein kinase A-independent inhibition of proliferation and induction of apoptosis in human thyroid cancer cells by 8-Cl-adenosine. J Clin Endocrinol Metab: 2008; 93 1020 1029
75. Robinson-White A J, Bossis I, Hsiao H P, Nesterova M, Leitner W W, Stratakis C A. 8-Cl-adenosine inhibits proliferation and causes apoptosis in B-lymphocytes via protein kinase A-dependent and independent effects: implications for treatment of Carney complex-associated tumors. J Clin Endocrinol Metab: 2009; 94 4061 4069